Barchart.com's Chart of the Day - Catalyst Pharmaceuticals Partners
Related Stocks
 CPRX - Catalyst Pharm Inc
SymLastChgPct
CPRX4.17-0.03-0.71%
The Chart of the Day belongs to Catalyst Pharmaceutical Partners (CPRX)/  I found the pharmaceutical stock by using Barchart to sort today's 52 Week High list first by the highest Weighted Alpha, Then I used thr Flipchart feature to review the charts for consistent price appreciation.  Since the Trend Spotter signaled a buy in 10/20 the stock gained 55.80%

Catalysts Pharmaceutical Partners is a biopharmaceutical company focused on the development and commercialization of prescription drugs for the treatment of addiction and obsessive compulsive disorders. The Company has obtained from Brookhaven National Laboratory an exclusive worldwide license for Brookhaven's patent portfolio in the US relating to the right to use vigabatrin to treat a wide variety of substance addictions and obsessive compulsive disorders. Catalyst has also been granted rights to Brookhaven's vigabatrin-related foreign patents or patents pending worldwide. The Company's initial product candidate based on vigabatrin is CPP-109. CPP-109 has been granted `Fast Track` status by the U.S. Food & Drug Administration for the treatment of cocaine addiction. This indicates that the FDA has recognized that CPP-109 is intended for the treatment of a serious or life-threatening condition for which there is no effective treatment and which demonstrates the potential to address unmet medical needs.

Barchart Technical indicators:
  • 248.10+ Weighted Alpha
  • 100% tecnical buy signals
  • Trend Spotter buy signal
  • Above its 20, 50 and 100 day moving averages
  • 12 new hihgs and up 62.26% in the last month
  • Relative Strength Index 85.47%
  • Technical support level at 4.04
  • Recently traded at 4.30 with a 50 day moving average of 2.88

Fundamental factors:
  • Market Cap $370 million
  • Although none of the Wall Street analysts have given projections on Revenue and Earnings 4 have issued strn buy recommendations
  • The individual investors following the stock on Motley Fool voted 60 to 11 that the stock would beat the marlet